Cadrenal Therapeutics Advances CAD-1005 for HIT After Positive Phase 2 Data and FDA Meeting — Cadrenal Therapeutics, Inc.

Event summary

Cadrenal Therapeutics reported a >25% absolute reduction in thrombotic events in the CAD-1005 treatment arm versus placebo in a Phase 2 study for HIT.
Completed End-of-Phase 2 meeting with FDA on March 26, 2026, clarifying the registrational path for the planned Phase 3 pivotal trial of CAD-1005.
Reported Q4 2025 net loss of $3.0 million, down from $4.2 million in Q4 2024, with cash and cash equivalents of $4.0 million as of December 31, 2025.

The big picture

Cadrenal Therapeutics is positioning CAD-1005 as a potential breakthrough treatment for heparin-induced thrombocytopenia (HIT), a life-threatening condition with high mortality rates. The positive Phase 2 data and FDA meeting progress highlight the strategic importance of selective 12-LOX inhibition in addressing unmet medical needs. However, the company's financial sustainability remains a critical factor as it evaluates financing options to support its development plans.

What we're watching

Regulatory Pathway: How the FDA's feedback will shape the Phase 3 protocol and timeline for CAD-1005.
Financial Sustainability: Whether Cadrenal can secure sufficient financing to support its planned clinical development activities.
Pipeline Expansion: The pace at which Cadrenal advances its broader 12-LOX platform and other pipeline assets beyond HIT.